I hope for the day when women will not be able to identify with me, when doctors will take out the cancer and leave the woman intact.
My hope is close thanks to research companies like TeVido Bio Devices. TeVido is a biotech company in the early-stage of developing 3D bio-printing of live cells to rebuild the NAC (nipple areola complex) for breast cancer patients and, in time, the entire breast. Yes, that’s right, take away the diseased breast and print out a new one made of you!
I would like the photos on this site to bring attention to this technology. It is my hope to hang these portraits in offices, malls or clinics directing intrigued individuals to my website, LoveLydia.net, where you can learn more about TeVido and others who are on this journey with me and how you can help to make this hope a reality.
TeVido BioDevices is a privately held biotechnology company using 3D bio-printing of a woman’s own living cells – to build custom grafts for breast cancer reconstruction. Our first product is targeted to improve nipple reconstruction and later fill lumpectomies and other fat grafting needs.
For the majority of women who undergo breast reconstruction, the final step in the process involves the nipple areola complex (NAC). Studies highlight that patients with loss of the nipple and areola continue to experience psychological distress even long after breast mound reconstruction has taken place and recreation of the nipple-areola complex has a high correlation with overall patient satisfaction and acceptance of body image. Most women who have reconstruction also opt for some type of NAC reconstruction. Unfortunately, results of currently available NAC reconstruction techniques are unpredictable. TeVido is developing propriety, patent-pending, bioprinting technology, CellatierTM, and when combined with a woman’s own living cells will build a custom NAC graft made just for her.
Globally, in 2010, nearly 1.5 million were told “you have breast cancer” and in the US in 2013 it is estimated to be more than 296,000; nearly 40% of women opt for mastectomy, or full removal of the breast tissue for their cancer treatment regime – of those 24% will have a double mastectomy, removing both breasts. Approximately 1/3 of mastectomy patients will decide to undergo breast reconstruction and women with double mastectomies have double the rates of reconstruction.
Longer term, as CellatierTM technology is matured, a second opportunity in breast reconstruction is to address the unmet challenge in filling lumpectomy voids. Approximately 60% of women will opt for lumpectomy treatment, of those, at least 25% are dissatisfied with the physical outcome of the remaining breast tissue and those women were far more likely to experience symptoms of depression and fear of cancer recurrence compared to women with minimal asymmetry. However few reconstructive options exist for lumpectomies. Women undergoing lumpectomies to remove tumors or breast cancer are faced with limited options if they are unhappy with the physical outcome of their breast: spend months filling the void with a series of fat injections, which then have the potential to be reabsorbed into the body; or do nothing, which can leave breasts disfigured and asymmetrical. An adjacent market exists for soft tissue reconstruction for other conditions such as sport and war related injuries resulting in tissue deficiency as well as the rare soft tissue sarcomas of the extremities. These conditions have significant quality of life impacts for the patient.